<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1171</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>14722270</PubmedId>
            <Abstract>Both CD4(+) and CD8(+) T cells are required for clearance of the murine coronavirus mouse hepatitis virus (MHV) during acute infection. We investigated the effects of an epitope-specific CD8(+) T-cell response on acute infection of MHV, strain A59, in the murine CNS. Mice with CD8(+) T cells specific for gp33-41 (an H-2D(b)-restricted CD8(+) T-cell epitope derived from lymphocytic choriomeningitis glycoprotein) were infected with a recombinant MHV-A59, also expressing gp33-41, as a fusion protein with enhanced green fluorescent protein (EGFP). By 5 days postinfection, these mice showed significantly (approximately 20-fold) lower titers of infectious virus in the brain compared to control mice. Furthermore mice with gp33-41-specific CD8(+) cells exhibited much reduced levels of viral antigen in the brain as measured by immunohistochemistry using an antibody directed against viral nucleocapsid. More than 90% of the viruses recovered from brain lysates of such protected mice, at 5 days postinfection, had lost the ability to express EGFP and had deletions in their genomes encompassing EGFP and gp33-41. In addition, genomes of viruses from about half the plaques that retained the EGFP gene had mutations within the gp33-41 epitope. On the other hand, gp33-41-specific cells failed to protect perforin-deficient mice from infection by the recombinant MHV expressing gp33, indicating that perforin-mediated mechanisms were needed. Virus recovered from perforin-deficient mice did not exhibit loss of EGFP expression and the gp33-41 epitope. These observations suggest that the cytotoxic T-cell response to gp33-41 exerts a strong immune pressure that quickly selects epitope escape mutants to gp33-41.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>1150-9</ArticlePages>
            <ArticleTitle>Effects of an epitope-specific CD8+ T-cell response on murine coronavirus central nervous system disease: protection from virus replication and antigen spread and selection of epitope escape mutants.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Chua</LastName>
                    <ForeName>Ming Ming</ForeName>
                </Author>
                <Author>
                    <LastName>MacNamara</LastName>
                    <ForeName>Katherine C</ForeName>
                </Author>
                <Author>
                    <LastName>San Mateo</LastName>
                    <ForeName>Lani</ForeName>
                </Author>
                <Author>
                    <LastName>Shen</LastName>
                    <ForeName>Hao</ForeName>
                </Author>
                <Author>
                    <LastName>Weiss</LastName>
                    <ForeName>Susan R</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6076, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Epitopes;Glycoproteins;Luminescent Proteins;Membrane Glycoproteins;Peptide Fragments;Pore Forming Cytotoxic Proteins;Recombinant Fusion Proteins;Viral Proteins;glycoprotein peptide 33-41, Lymphocytic choriomeningitis virus;Perforin;Green Fluorescent Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigens, Viral(immunology; metabolism); CD8-Positive T-Lymphocytes(immunology); Central Nervous System Viral Diseases(immunology; prevention &amp; control); Coronavirus Infections(immunology; prevention &amp; control); Epitopes(genetics; immunology); Glycoproteins(immunology); Green Fluorescent Proteins; Humans; Immunization; Luminescent Proteins(genetics; immunology); Membrane Glycoproteins(genetics; metabolism); Mice; Mice, Inbred C57BL; Murine hepatitis virus(genetics; immunology; pathogenicity); Mutation; Peptide Fragments(immunology); Perforin; Pore Forming Cytotoxic Proteins; Recombinant Fusion Proteins(genetics; immunology); Viral Proteins(immunology); Virus Replication</ArticleMeshHeadingsList>
            <Journal>
                <Volume>78</Volume>
                <Issue>3</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>gp33-41</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KAVYNFATC</LinearSequence>
                        <StartingPosition>33</StartingPosition>
                        <EndingPosition>41</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>ABI96818.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11623</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>30001</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 4A, 5, 6A and Table 2</LocationOfData>
                        <TCellId>16652</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>4 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KAVYNFATC</LinearSequence>
                                            <StartingPosition>33</StartingPosition>
                                            <EndingPosition>41</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>ABI96818.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>rLm-gp33</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>1639</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. with 10&lt;sup&gt;4&lt;/sup&gt; CFU recombinant Listeria monocytogenes (rLm) expressing the LCMV (H-2Db) gp33-41 epitope as a fusion partner with dihydrofolate reducatase in 0.5ml PBS. Two weeks later they were infected with recombinant murine hepatitis virus (MHV) expressing gp33. These experiments were repeated using perforin-deficient PKO mice.</ImmunizationComments>
                        </Immunization>
                        <AntigenPresentingCells>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>rMHV-pg33</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATC</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABI96818.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <RecombinantOrganism>
                                    <SubType>Recombinant Organism</SubType>
                                    <RecombinantOrganismId>11142</RecombinantOrganismId>
                                </RecombinantOrganism>
                            </AntigenContainingObject>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Mice previously immunized with rLm expressing the epitope have statistically significant lower titers of infectious virus in the brain at day 5 post-infection. There is an approximately 20-fold reduction of titer in mice immunized with the gp33 epitope, but not in control mice inoculated with a sham peptide, rLm-np118, or mice inoculated with virus only. In a separate experiment performed using perforin-deficient PKO mice, protection was not achieved in the absence of perforin.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 2, 4B and 6B</LocationOfData>
                        <TCellId>16651</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>4 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KAVYNFATC</LinearSequence>
                                            <StartingPosition>33</StartingPosition>
                                            <EndingPosition>41</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>ABI96818.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>11623</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11142</RecombinantOrganismId>
                                        <SourceMolecule>
                                            <GenBankId>P42212.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>6100</MoleculeSourceOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose 10&lt;sup&gt;4&lt;/sup&gt; PFU MHV</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. (10&lt;sup&gt;4&lt;/sup&gt;PFU) or i.c. (2x10&lt;sup&gt;3&lt;/sup&gt;PFU) with recombinant murine hepatitis virus (MHV) expressing the LCMV  (H-2Db) gp33-41 as a fusion partner with enhanced GFP.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>Mononuclear cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KAVYNFATC</LinearSequence>
                                        <StartingPosition>33</StartingPosition>
                                        <EndingPosition>41</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>ABI96818.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11623</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific IFNg expression was observed in the CNS and spleens of mice infected with rMHV expressing the LCMV epitope. Intraperitoneal or intracranial inoculation elicited the same response. The immune response against the epitope following infection with rMHV-gp33 in animals that had been immunized with rLm-gp33 was greatly enhanced compared with that of mice inoculated with sham peptide, rLm-np118, or mice that were not inoculated with Listeria. Mice that had been immunized with rLm-gp33 and subsequently infected with rMHV-gp33 had much higher levels of epitope-specific, IFNg-positive CD8+ T cells than did animals inoculated with sham peptide. In PKO mice, lack of protection was not due to a lack of a gp33 epitope-specific CD8+ T-cells, but rather to perforin deficiency.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>MHV S598</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RCQIFANI</LinearSequence>
                        <StartingPosition>546</StartingPosition>
                        <EndingPosition>553</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P11224.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11142</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Cited Reference</LocationOfData>
                <EpitopeId>53307</EpitopeId>
                <ReferenceStartingPosition>598</ReferenceStartingPosition>
                <ReferenceEndingPosition>605</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Exact match to reference information</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope sequence was provided in cite reference Castro et al. J Virol 1995;69:8127 [PMID: 7494335].</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>1863871</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Age>4 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>11142</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideSequence>KAVYNFATC</PeptideSequence>
                                        <PeptideModifications/>
                                        <PeptideSourceMolecule>
                                            <GenBankId>ABI96818.1</GenBankId>
                                        </PeptideSourceMolecule>
                                        <PeptideSourceOrganismId>11623</PeptideSourceOrganismId>
                                        <SourceMolecule>
                                            <GenBankId>P42212.1</GenBankId>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>6100</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose 10&lt;sup&gt;4&lt;/sup&gt; PFU MHV</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected i.p. (10&lt;sup&gt;4&lt;/sup&gt;PFU) or i.c. (2x10&lt;sup&gt;3&lt;/sup&gt;PFU) with recombinant murine hepatitis virus (MHV) expressing the LCMV  (H-2Db) gp33-41 as a fusion partner with enhanced GFP.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Central nervous system (CNS)</CellTissueType>
                            <CellType>Mononuclear cell</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RCQIFANI</LinearSequence>
                                        <StartingPosition>546</StartingPosition>
                                        <EndingPosition>553</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P11224.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>11142</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Epitope-specific IFNg expression was observed in the CNS of mice infected with rMHV expressing the foreign LCMV epitope. Splenocytes were negative. Intraperitoneal or intracranial inoculation elicited this response.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

